A Clinical Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic People With Schizophrenia, Followed by an Open-label Extension Phase

• Sponsor: Sumitomo Pharma Co., Ltd. (Industry)
• Overall Status: Recruiting
• CT.gov ID: NCT04825860
• Collaborator: (none)
• Enrollment: 480
• Locations: 25
• Arms: 3
• Anticipated Duration (Months): 51.1
• Patients Per Site: 19.2
• Patients Per Site Per Month: 0.4

Study Details

Study Description

Brief Summary

A clinical study to investigate the effect of 2 doses of an investigational drug in acutely psychotic adult patients with schizophrenia. The study will consist of a double-blind phase followed by an open-label extension phase.

Condition or Disease	Intervention/Treatment	Phase
Schizophrenia	Drug: SEP-363856 50 mg; Drug: SEP-363856 75 mg; Drug: Placebo	Phase 2/Phase 3

Detailed Description

A Phase 2/3 Randomized, Double-blind, Parallel-group, Placebo-controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Patients with Schizophrenia, Followed by an Open-label Extension Phase.

The double-blind phase is to evaluate the efficacy and safety of 2 doses of SEP-363856 (50 and 75 mg/day) versus placebo over 6 weeks in acutely psychotic patients with schizophrenia. This phase is projected to randomize approximately 480 subjects to 3 treatments (SEP-363856 50 mg/day, SEP-363856 75 mg/day, placebo) in a 1:1:1 ratio. The completers of the double-blind phase will be able to enroll into the 12-week open-label phase during which the long term safety and effectiveness of-SEP 363856 will be evaluated.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 480 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Randomized, Double-blind, Parallel-group, Placebo Controlled, Fixed-dose, Multicenter Study to Evaluate the Efficacy and Safety of SEP 363856 in Acutely Psychotic Patients With Schizophrenia, Followed by an Open-label Extension Phase
• Actual Study Start Date: Mar 29, 2021
• Anticipated Primary Completion Date: Mar 31, 2025
• Anticipated Study Completion Date: Jun 30, 2025

Arms and Interventions

Arm	Intervention/Treatment
Experimental: SEP-363856 50 mg/day Subjects randomized to the SEP-363856 50 mg/day group will receive the assigned dose of SEP-363856 50 mg/day throughout the double-blind phase.	Drug: SEP-363856 50 mg; Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Experimental: SEP-363856 75 mg/day Subjects randomized to the SEP-363856 75 mg/day group will receive SEP-363856 50 mg/day on Day 1 through Day 3 and then the assigned dose of SEP-363856 75 mg/day thereafter.	Drug: SEP-363856 75 mg; Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.
Placebo Comparator: Placebo Subjects randomized to the placebo group will receive placebo throughout the double-blind phase.	Drug: Placebo; Subjects will take one tablet of study drug per day at approximately the same time each evening at bedtime. Study drug may be taken orally with or without food.

Outcome Measures

Primary Outcome Measures

1. Change from Baseline in Positive and negative syndrome scale (PANSS) total score at Week 6 [Week 6]

   PANSS is comprised of 30 items and 3 subscales (Positive, Negative, General Psychopathology). An anchored Likert scale from 1 - 7, where values of 2 and above indicate the presence of progressively more severe symptoms, is used to score each item. Individual items are then summed to determine scores for the 3 subscales, as well as a total score. PANSS Positive subscale score range: 7-49. PANSS Negative subscale score range: 7-49. PANSS General Psychopathology subscale score range: 16-112. PANSS total score range: 30-210.

Secondary Outcome Measures

1. Change from Baseline in Clinical Global Impressions - Severity (CGI-S) score at Week 6 [Week 6]

   The CGI-S is a single-item clinician-rated assessment of the subject's current illness state on a 7-point scale (score range: 1-7), where a higher score is associated with greater illness severity.

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 65 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Must be fully informed of and understand the objectives, procedures, and possible benefits and risks of the study, and give written informed consent prior to performing any study related activities. If the subject is considered a minor according to local regulations at the time of collection of the informed consent, written consent will be obtained from a legally acceptable representative (guardian) in addition to that obtained from the subject.

2. Male or female between 18 to 65 years of age (inclusive) at the time of consent.

3. Must meet DSM 5 criteria for schizophrenia as established by clinical interview at Screening

4. Must have a CGI S score ≥ 4 (moderately ill) at Screening and Baseline.

5. Must have a PANSS total score ≥ 80 and a PANSS item score ≥ 4 (moderate) on 2 or more of the following PANSS items: delusions (P1), conceptual disorganization (P2), hallucinations (P3), and unusual thought content (G9) at Screening and Baseline.

6. Must have an acute exacerbation of psychotic symptoms (no longer than 2 months prior to providing informed consent for this study). The acute exacerbation should include:

1. Marked deterioration of functioning in one or more areas, such as occupational, social, or personal care or hygiene.

1. In the opinion of the Investigator, subjects must be generally healthy based on Screening medical history, physical examination (PE), vital signs, ECG, and clinical laboratory values (hematology, chemistry, and urinalysis).

Exclusion Criteria:

1. Have a DSM 5 diagnosis or presence of symptoms consistent with a DSM 5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder (within past 12 months), substance (other than nicotine or caffeine) use disorder within past 12 months, or lifetime history of significant substance abuse that, in the opinion of the Investigator, may have had a significant and potentially permanent impact on the brain or other body systems, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms have not been a focus of primary treatment

2. At significant risk of harming self, others, or objects based on Investigator's judgment.

3. Have any clinically significant unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.

4. Female subjects who are pregnant or lactating.

5. Have any clinically significant abnormal laboratory value(s) at Screening (hematology, chemistry, and urinalysis) as determined by the Investigator.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Hotei Hospital	Konan	Aichi	Japan
2	Medical corporation Seijinkai Seinan Hospital	Hachinohe	Aomori	Japan
3	Kohnodai Hp., National Center for Global Health and Medicine	Ichikawa	Chiba	Japan
4	Shiranui Hospital	Omuta	Fukuoka	Japan
5	Takeda General Hospital	Aizu-Wakamatsu	Fukushima	Japan
6	Mihara Hospital	Mihara	Hiroshima	Japan
7	Okinawa Tokushukai Hino Hospital	Yokohama	Kanagawa	Japan
8	Yatsushiro Kosei Hospital	Yatsushiro	Kumamoto	Japan
9	Shonan Hospital	Matsumoto	Nagano	Japan
10	Mental Support Soyokaze Hospital	Ueda	Nagano	Japan
11	NHO Ryukyu Hospital	Kunigami	Okinawa	Japan
12	Social welfare corporation Tenshinkai Kosaka hospital	Higashiosaka	Osaka	Japan
13	Nishiurakai Keihan Hospital	Moriguchi	Osaka	Japan
14	Neyagawa Sanatorium	Neyagawa	Osaka	Japan
15	Asakayama Hospital	Sakai	Osaka	Japan
16	Osaka Institute of Clinical Psychiatry Shin-abuyama Hospital	Takatsuki	Osaka	Japan
17	NHO Hizen Psychiatric Center	Kanzaki	Saga	Japan
18	Rainbow & Sea Hospital	Karatsu	Saga	Japan
19	Nishi Kumagaya Hospital	Kumagaya	Saitama	Japan
20	Shiga university of medical science hospital	Otsu	Shiga	Japan
21	Narimasu Kosei Hospital	Itabashi	Tokyo	Japan
22	Akino Hospital	Tendo	Yamagata	Japan
23	Akita City Hospital	Akita		Japan
24	Inokuchi Noma Hospital	Fukuoka		Japan
25	Kuramitsu Hospital	Fukuoka		Japan

Sponsors and Collaborators

• Sumitomo Pharma Co., Ltd.

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Sumitomo Pharma Co., Ltd.
• ClinicalTrials.gov Identifier: NCT04825860
• Other Study ID Numbers: DA801201; jRCT2071210003
• First Posted: Apr 1, 2021
• Last Update Posted: Apr 12, 2022
• Last Verified: Apr 1, 2022

• Individual Participant Data (IPD) Sharing Statement: No
• Plan to Share IPD: No
• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Additional relevant MeSH terms: Schizophrenia

Study Results

No Results Posted as of Apr 12, 2022